Align Clinical CRO: Leading CROs Form New Industry Standards Group to Improve Collaboration with Sponsors
Six leading contract research organizations (CROs) and Veeva Systems (NYSE:VEEV) today introduced Align Clinical CRO, a new industry standards group dedicated to making it easier for sponsors and CROs to work together during clinical trials. Founding members, with input across the industry, plan to help create open technology standards intended to improve trial execution and collaboration with life sciences companies.
For the first time, leading CROs, including ICON plc, Medpace, Pharmaceutical Product Development, LLC (PPD), PRA Health Sciences, Syneos Health, and UBC are coming together to develop open technology standards to transform clinical trial operations across the entire industry to speed product development.
“There is tremendous potential to enhance clinical trial execution with common technology standards that benefit the entire industry,” said Henry Levy, president of Align Clinical CRO. “The assembly of Align Clinical CRO represents an important industry collaboration to improve the trial process and how the industry works together to accelerate drug development.”
Align Clinical CRO will create open technology standards intended to help increase sponsor and CRO productivity, reduce operational costs, and run trials faster. The group’s first standard is anticipated to be an Operational Data Exchange standard to facilitate seamless information sharing between sponsors and CROs. This is expected to include the definition of a technical standard for data to be exchanged between a sponsor and a CRO relating to the operational execution of a trial, including key metrics and milestone information.
CROs play an integral role in supporting drug development, with clinical outsourcing expected to increase to 50% by 2020.1 As sponsors run a growing number of trials with multiple CROs, developing pre-competitive industry standards will help bring more consistency to trial management and address the complexity of trial oversight to make drug development processes more efficient.
Align Clinical CRO will post its Operational Data Exchange standard for public review and input later this year, which will also be reviewed and considered as part of the adoption of proposed standards. Visit AlignClinicalCRO.org to learn about the group’s mission and stay up-to-date on the standards in development.
What Align Clinical CRO Members Are Saying:
“Leading experts are coming together in Align Clinical CRO to streamline how data is shared between CROs and sponsors during trials,” said Thomas O’Leary, chief information officer at ICON plc. “We look forward to contributing to the group and creating standards that drive greater speed and productivity across the industry.”
“Align Clinical CRO will play an important role in helping the industry accelerate innovation and get new treatments to patients faster,” said Mark Roseman, senior vice president of clinical operations at Medpace. “We are excited to join forces with like-minded CROs that want to move the industry forward and make clinical trial execution more efficient.”
“This is the first time CROs are coming together to make this commitment to transform clinical trials across our industry and we are excited to be part of this effort,” said Michael Brooks, executive vice president of product registration at PRA Health Sciences. “This shows our mutual commitment to make the drug development process more efficient and to help bring needed therapies to market more quickly.”
“Align Clinical CRO will help speed the timeline for gaining new therapy approvals for patients,” said Rachel Stahler, chief information officer at Syneos Health. “By creating a vehicle for CROs to collaborate and share actionable insight with sponsors, we can improve operational delivery and streamline the increasingly complex trial process.”
“UBC is excited to join Align Clinical CRO,” said Brett Huselton, senior vice president of commercial strategy for product and opportunity development at UBC. “We are committed to developing open technology standards that benefit the entire industry and make clinical trial processes more efficient.”
About Align Clinical CRO
Align Clinical CRO is an industry standards group founded by Veeva Systems and the world’s largest CROs, including ICON plc, Medpace, Pharmaceutical Product Development LLC (PPD), PRA Health Sciences, Syneos Health, and UBC. The group is dedicated to creating open technology standards that improve trial execution and collaboration with life sciences companies, making it easier for sponsors and CROs to work together during clinical trials. For more information, visit www.alignclinicalcro.org.
1 CRO Industry Primer: A 2016 Credit Suisse Research Analysis, June 2016
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Dataiku Raises $101 Million Series C to Transform and Democratize Enterprise AI Globally19.12.2018 15:00 | Pressemelding
Dataiku Inc., one of the world’s leading enterprise data science and machine learning platforms, today announced a $101 million Series C funding round led by ICONIQ Capital and supported by Alven Capital, Battery Ventures, Dawn Capital, and FirstMark Capital. This announcement follows the company’s $28 million Series B in September 2017 and the release of Dataiku 5 in September 2018. Since its founding in 2013, Dataiku has focused on the vision of democratized data science as the key to uninhibited possibilities instead of restricted technologies reserved for the elite few. Today, Dataiku provides a platform that enables enterprises to fundamentally transform their business - global leaders use it to build AI that optimizes marketing budget, enables maintenance services, anticipate market trends or detects fraud, and more. “We’re very excited about what this latest funding round represents - it’s a confirmation of our vision to build and deliver the missing block for the modern enterpr
Universal Laser Systems Expands Its Materials Database with AOK Technologies, Solvay and 3M Materials19.12.2018 13:05 | Pressemelding
Universal Laser Systems (ULS) announces the addition of AOK Technologies, Solvay and 3M™ materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The AOK Technologies, Solvay, and 3M materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: AOK Technologies TCK6 Thermally Conductive Insulator AOK Technologies TC1200 Thermally Conductive Insulator Solvay Udel® P-1700 Polysulfone (PSU) Solvay Ajedium™ Film Ultem® 1000-1000 Polyetherimide (PEI) 3M™ 1538L Rayon Acetate Woven Fabric Medical Tape Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advanta
Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases19.12.2018 13:01 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181219005363/en/ Under the collaboration, Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent TGFβ1 with high affinity and specificity, inhibitors that selectively target activation of latent TGFβ1 localized to extracellular matrix, and a third TGFβ discovery program. Scholar Rock is responsible for antibody discovery and preclinical research through product candidate nomination, after which, upon exercising the option for a program, Gilead will be resp
Boeing-Leonardo Team Selects FLIR Systems EO/IR Surveillance Sensors for US Strategic Command UH-1N Replacement Contract19.12.2018 13:00 | Pressemelding
FLIR Systems, Inc. (NASDAQ: FLIR) announced today it has been selected by Boeing to provide the FLIR Star SAFIRE 380-HDc EO/IR surveillance sensor for the United States Air Force (USAF) UH-1N replacement contract. The replacement program will replace the current fleet of USAF UH-1N helicopters, which support the service’s nuclear intercontinental ballistic missile bases in Wyoming, Montana and North Dakota. The aircraft will also be used for training, test and operational support airlift missions. The initial contract award to FLIR is for the first four helicopters, with the total contract up to 84 MH-139 helicopters and valued at more than $40 million to FLIR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181219005203/en/ FLIR will provide its Star SAFIRE 380-HDc airborne surveillance camera as part of the Boeing-Leonardo UH-1N replacement contract (Photo: Business Wire) Boeing was awarded a $375.5 million firm-fixed-price
BOC Group Listed as a Representative Vendor in the 2018 Gartner Market Guide for Enterprise Business Process Analysis19.12.2018 12:00 | Pressemelding
The leading global provider of Enterprise Management Solutions, BOC Group, is pleased to share its recognition for its BPM suite ADONIS NP, in Gartner's latest Market Guide for Enterprise Business Process Analysis * . Thereby, BOC Group continues its recognition from the October 2018 Gartner Magic Quadrant and Critical Capabilities for Enterprise Architecture Tools reports for its EA suite ADOIT. Tobias Rausch, ADONIS product manager comments: “We are happy about getting recognized by Gartner, for the second time now, in their recently published Market Guide for Enterprise Business Process Analysis report. We see our placement in this year’s Market Guide as a testimony to our cutting-edge Business Process Analysis offering, and a validation that our strong focus on BPA is helping businesses in the digital transformation of their enterprise.” The Business Transformation Suite ADONIS NP is BOC Group's flagship product and Business Process Management and Analysis tool. This fully web-base
Slice Launch Studio Opens to Insurers and Tech Companies to Create Digital Insurance Products19.12.2018 12:00 | Pressemelding
Slice Labs Inc., a leading on-demand insurance cloud platform provider, announced today the opening of the Slice Launch Studio in downtown Toronto, which is designed to be an innovation hub for Slice and its partners to ideate, experiment, test and deploy new on-demand insurance products on the Slice Insurance Cloud Services (ICS) platform. Insurers and technology companies from around the world can come to the Launch Studio to collaborate on Hackathons, a key step in Slice’s approach to getting product to market quickly. Slice will also host events year-round, bringing together thought leaders from across the globe to discuss and address emerging and increasing risks. Slice is currently working with insurers in the U.S., Canada, UK and SE Asia to launch new on-demand insurance products, using a minimum viable product methodology which allows for launch in under three months. The Co-operators Group is the pilot partner for the Launch Studio, who recently launched duuo, both its new dig